Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Cognitive Enhancement Research Dihexa Dihexa has been directly tested in cognitive paradigms (aged rat water maze, scopolamine reversal) and demonstrates synaptogenesis through HGF/c-Met signaling, providing a more direct cognitive enhancement rationale than PE-22-28 Neurogenesis and Mood Research PE-22-28 PE-22-28 induces hippocampal neurogenesis within 4 days and demonstrates antidepressant-like effects through TREK-1 blockade, making it more relevant for mood-cognition intersection research Oral Bioavailability Requirement Dihexa Dihexa has demonstrated approximately 38% oral bioavailability with BBB penetration, while PE-22-28 oral availability has not been characterized Lower Theoretical Risk Profile PE-22-28 PE-22-28 targets an ion channel without known oncological associations, whereas Dihexa activates the HGF/c-Met pathway which is a characterized oncogenic signaling axis Evidence Reliability PE-22-28 PE-22-28 has no retracted publications in its evidence base, while a key 2014 Dihexa paper was retracted for data fabrication concerns Continue Your Research Get comparison updates We publish new head-to-head comparisons regularly
Risk factors associated with prolonged hospital stay and readmission in patients after primary bariatric surgery
International Journal of Exercise Science , 13 , 10631071
doi: 10.1210/endocr/bqad133 144
US$ 20.32
US$ 22.16
US$ 28.03
